1. Home
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
T-Cell Lymphoma Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)

T-Cell Lymphoma Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)

  • May 2021
  • 132 pages
  • ID: 6039464
  • Format: PDF
  • Mordor Intelligence LLP


Table of Contents

Search Inside

The Global T-Cell Lymphoma Market was valued at USD 1,547.04 million in 2020, and it is expected to reach USD 2509.94 million by 2026, registering a CAGR of 8.25% during the period of 2021-2026.

Due to the high transmission rate of COVID_19 and lack of treatment, many countries suffered, and they are continuing to bear a significant burden on both their economies and healthcare systems. The COVID-19 outbreak may put patients with cutaneous lymphomas at additional risk of not receiving the necessary diagnostic procedures and treatment because they cannot access hospitals easily or due to healthcare resources limitations. Several guidelines for managing cutaneous lymphoma have been recently published to help dermatologists choose the right approach in the COVID-19 pandemic. However, these guidelines happen to be not applicable in countries that are still under a lockdown or do not have enough resources to implement the plan.

Moreover, the outbreak of COVID-19 impacted the cancer T-cell lymphoma market, as hospitals and healthcare services were significantly reduced due to social distancing measures enforced globally. The COVID-19 pandemic also affected the global economy and showed a huge impact on the general hospital care functioning for non-COVID-19 patients in hospitals across the world.

The growth of the T-Cell Lymphoma Market is attributed to the rise in lymphoma cancer incidence due to radiations, an increase in the number of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders.

According to Leukemia & Lymphoma Society 2020, an estimate of 85,720 new cases of lymphoma has been diagnosed in United States in the year 2020. In addition, the new reported lymphoma cases includes 8,480 cases of Hodgkin (HL), 77,240 cases Non-Hodgkin (NHL) Lymphoma. Moreover, there are around 644,761 people living with or in remission from non-Hodgkin lymphoma according to the same source in 2020. T-cell lymphoma is significantly contributing to non-Hodgkin lymphoma which further boosts the overall market growth.

In addition, the growing uptake of premium-priced products such as Keytruda, Opdivo and immune checkpoint inhibitors and the launch of several novel therapies with label extension of commercialized products are also boosting the overall market growth. However, high cost associated with T-cell lymphoma treatment and the adverse side effects of therapies have been obstructing the overall market growth.

Key Market Trends
Chemotherapy is Expected to Hold Significant Market Share over the Forecast Period

Chemotherapy is the most common form of therapeutics used to stop or slow down the growth of cancer cells. Surgery and radiation therapy works by removing, killing, or damaging the cancer cells in a particular area, but chemotherapy works throughout the whole body. This means that chemotherapy can destroy and damage cancer cells that have spread to other parts of the body away from the original tumor.

According to European Society for Medical Oncology, the COVID-pandemic had generated a huge backlog in oncology care and research. In addition, Cancer care was hit by the COVID-19 infection due to the halt in diagnostic procedures and surgical procedures. Moreover, as per many studies, cancer patients are more susceptible to coronavirus than individuals without cancer, as they are in an immunosuppressive state caused by the malignancy and anticancer treatment.

For instance, s per American Society of Clinical Oncology, Chemotherapy treatments and follow-ups were postponed during COVID-19 pandemic. Even private clinics in major Indian cities reported a nearly 50% decrease in patients for cancer care. Overall cancer services declined by 50% in April and May 2020.

Chemotherapy is used with surgery or radiation therapy, or both. In some cases, it is used in combination with other drugs, such as hormone therapy, targeted therapy, or immunotherapy. For example, chemo may be used to shrink a tumor before surgery or radiation therapy. Chemo used in this way is called neoadjuvant therapy or after surgery or radiation therapy to help kill any remaining cancer cells in the body. Chemo used in this way is called adjuvant therapy.

There are several types of chemotherapy being given to T-cell lymphoma patients, which include alkylating agents, plant alkaloids, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, and miscellaneous antineoplastics.

Favorable reimbursement policies with respect to these drugs making them accessible and affordable are expected to positively impact the market studied. For instance, Pralatrexate is a chemotherapy drug that is used in the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) is listed under the PBS scheme by the Australian government.

Thus, with the rising awareness about the benefits of chemotherapy and favorable government policies, the market studied is expected to flourish during the forecast period.

North America Dominates the Market and it is Expected to do the Same over the Forecast Period

Some of the factors driving the market growth in North America region include high prevalence of T-cell lymphoma, presence of key market players and increasing research and development activities.

The outbreak of COVID-19 impacted the cancer T-cell lymphoma market, as hospitals and healthcare services were significantly reduced due to social distancing measures enforced in North America region. Some biopharmaceutical companies, such as Merck & Co. Inc. and Eli Lilly and Company, announced clinical trial delays. For instance, as per data from ClinicalTrials.gov showed that more than 200 interventional oncology studies were suspended in March and April 2020, as a result of the COVID-19 crisis. In addition, 60% of institutions in the United States are enrolling new patients at a lower rate.

According to the Globocan 2020 report, Canada had 8,506 cases of Non-Hodgkin lymphoma and 313 deaths caused due to it in 2020. This is expected to increase T-cell lymphoma incidence in the country. ? The increase in cases of Non-Hodgkin lymphoma is expected to boost the demand for treatment options, which is going to positively aid market development, as T-cell lymphomas are a type of Non-Hodgkin lymphoma.

Some of the major companies who operates in oncology segment in North America region are adopting several strategies such as collaboration and acquisition to strengthen its position in the T-cell lymphoma market. For instance, in August 2020 the company BostonGene Corporation announced the collaboration with The Weinstock Laboratory which is at Dana-Farber Cancer Institute, Inc.. The collaboration is focused on defining predictors of response to PI3 kinase inhibition in relapsed/refractory T-cell lymphomas. In addition, other companies, such as Amgen and Merck, have been working on developing cancer therapies for T-cell lymphomas. Hence the aforementioned factors are expected to fuel the market growth in this region.

Competitive Landscape
The T-Cell Lymphoma Market is highly competitive and consists of a few major players. Companies, like Johnson & Johnson (Janssen Pharmaceuticals Inc.), Novartis AG, Bristol Myers Squibb Company, Merck & Co. Inc, F. Hoffmann-La Roche Ltd, hold the substantial share in the market.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on